Winrevair (sotatercept) Letter of Medical Necessity
Winrevair (sotatercept) is a first-in-class treatment for pulmonary arterial hypertension added to background therapy. Prior authorization requires documented hemodynamics, functional class, and optimized background PAH therapy.
FDA-Approved Indications
- ● pulmonary arterial hypertension (WHO Group 1 PAH)
Why Winrevair Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Background PAH therapy not optimized (2-3 drug combination)
- 2. Right heart catheterization not documented
- 3. WHO Functional Class not specified
- 4. Hemodynamic criteria not met
- 5. Specialty pharmacy network requirement
What to Include in a Winrevair Letter of Medical Necessity
Document WHO Group 1 PAH confirmed by right heart catheterization (mPAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 WU), WHO Functional Class II-III, current background therapy (ERA + PDE5i ± prostacyclin), 6MWD, NT-proBNP levels, and echocardiographic findings.
Key clinical evidence to cite:
- ✓ STELLAR Phase 3 trial — significant improvement in 6-minute walk distance
- ✓ First-in-class activin signaling inhibitor for PAH
Relevant guidelines:
- 📖 CHEST/ATS 2024 PAH Treatment Guidelines
- 📖 ESC/ERS Pulmonary Hypertension Guidelines
Winrevair Prior Authorization Criteria
Standard criteria across major US payers for Winrevair. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Documented failure or contraindication to formulary alternatives
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Winrevair
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Winrevair Prior Authorization FAQ
Why was my Winrevair prior authorization denied?
The most common denial reasons for Winrevair are: Background PAH therapy not optimized (2-3 drug combination); Right heart catheterization not documented; WHO Functional Class not specified; Hemodynamic criteria not met; Specialty pharmacy network requirement.
What should a Winrevair Letter of Medical Necessity include?
Document WHO Group 1 PAH confirmed by right heart catheterization (mPAP ≥20 mmHg, PCWP ≤15 mmHg, PVR >2 WU), WHO Functional Class II-III, current background therapy (ERA + PDE5i ± prostacyclin), 6MWD, NT-proBNP levels, and echocardiographic findings.
Which payers cover Winrevair?
Winrevair is covered by major US payers including UnitedHealthcare, Aetna, Cigna, BCBS, Medicare Part B, though formulary tier and prior authorization criteria vary.